FCFrank A. W. Coumans

Frank A. W. Coumans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frank A. W. Coumans has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Edwin van der Pol

    Department of Laboratory Medicine, Laboratory Specialized Diagnostics & Research, Laboratory of Experimental Clinical Chemistry, Amsterdam UMC University of Amsterdam Amsterdam the Netherlands

    2 shared publications
  • Rienk Nieuwland

    B Department of Clinical Chemistry, Academic Medical Center , University of Amsterdam , The Netherlands

    2 shared publications
  • Ton G. van Leeuwen

    Amsterdam UMC

    2 shared publications
  • A. Sturk

    Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    1 shared publication
  • Anita N. Böing

    Department of Clinical Chemistry, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

    1 shared publication
  • Elmar L. Gool

    A Department of Biomedical Engineering and Physics, Academic Medical Center , University of Amsterdam , The Netherlands

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation

    by E. van der Pol, A. Sturk, T. van Leeuwen, R. Nieuwland, F. Coumans, the ISTH-SSC-VB Working group


  • Open Access

    Bulk immunoassays for analysis of extracellular vesicles

    by Frank A. W. Coumans, Elmar L. Gool, Rienk Nieuwland

    There is increasing clinical interest in extracellular vesicles (EV) for diagnostic and treatment purposes. This review provides an overview of bulk immunoassays to analyse EV. Western blot and enzyme-linked immunosorbent assay are still the two predominant bulk immunoassays. Recently, new assays have become available that can detect exposure to EV concentrations that are up to 10,000-fold lower. This is advantageous for applications that detect rare EV. Other important parameters are the detectable concentration range, the required sample volume, whether simultaneous presence of different antigens on a single EV can be detected, size selectivity of each assay and practical considerations. In this review, we will explain the working principles of the traditional and novel assays together with their performance parameters. The most sensitive assays are micro-nuclear magnetic resonance, surface plasmon resonance, and time-resolved fluorescent immunoassay.


  • Open Access

    Reproducible extracellular vesicle size and concentration determination with tunable resistive pulse sensing

    by Frank A. W. Coumans, Edwin van der Pol, Anita N. Böing, Najat Hajji, Guus Sturk, Ton G. van Leeuwen, Rienk Nieuwland

    Introduction: The size of extracellular vesicles (EVs) can be determined with a tunable resistive pulse sensor (TRPS). Because the sensing pore diameter varies from pore to pore, the minimum detectable diameter also varies. The aim of this study is to determine and improve the reproducibility of TRPS measurements.Methods: Experiments were performed with the qNano system (Izon) using beads and a standard urine vesicle sample. With a combination of voltage and stretch that yields a high blockade height, we investigate whether the minimum detected diameter is more reproducible when we configure the instrument targeting (a) fixed stretch and voltage, or (b) fixed blockade height.Results: Daily measurements with a fixed stretch and voltage (n=102) on a standard urine sample show a minimum detected vesicle diameter of 128±19 nm [mean±standard deviation; coefficient of variation (CV) 14.8%]. The vesicle concentration was 2.4·109±3.8·109 vesicles/mL (range 1.4·108–1.8·1010). When we compared setting a fixed stretch and voltage to setting a fixed blockade height on 3 different pores, we found a minimum detected vesicle diameter of 118 nm (CV 15.5%, stretch), and 123 nm (CV 4.5%, blockade height). The detected vesicle concentration was 3.2–8.2·108 vesicles/mL with fixed stretch and 6.4–7.8·108 vesicles/mL with fixed blockade height.Summary/conclusion: Pore‐to‐pore variability is the cause of the variation in minimum detected size when setting a fixed stretch and voltage. The reproducibility of the minimum detectable diameter is much improved by setting a fixed blockade height.


  • Open Access

    Detection of cancer before distant metastasis

    by Frank Aw Coumans, Sabine Siesling, Leon Wmm Terstappen

    Background: To establish a distant metastasis (DM) cells must disseminate from the primary tumor and overcome a series of obstacles, the metastatic cascade. In this study we develop a mathematical model for this cascade to estimate the tumor size and the circulating tumor cell (CTC) load before the first metastasis has formed from a primary breast cancer tumor. Methods: The metastatic cascade is described in discrete steps: 1. local tumor growth; 2. dissemination into circulation; 3. survival in circulation; 4. extravasation into tissue; and 5. growth into a metastasis. The model was built using data and relationships described in the literature to predict the relationship between tumor size and probability of distant metastasis for 38715 patients with surgically removed TXNXM0 primary breast cancer from the Netherlands Cancer Registry. The model was calibrated using primary tumor size, probability of distant metastasis and time to distant metastasis for 1489 patients with stage T1BNXM0 (25% of total patients with T1BNXM0). Validation of the model was done with data for all patients. Results: From the time to distant metastasis of these 38715 breast cancer patients, we determined a tumor doubling time of 1.7 ± 0.9 months. Fitting the data for 25% of T1B patients estimates a metastatic efficiency of 1 metastasis formed per 60 million disseminated tumor cells. Validation of the model to data of patients in all T-stages shows good agreement between model and epidemiological data. To reduce the 5-year risk of distant metastasis for TXNXM0 from 9.2% to 1.0%, the primary tumor needs to be detected and removed before it reaches a diameter of 2.7 ± 1.6 mm. At this size, the model predicts that there will be 9 ± 6 CTC/L blood. Conclusions: To reduce the rate of distant metastasis in surgically treated TXNXM0 breast cancer to 1%, imaging technology will need to be able to detect lesions of 2.7 mm in diameter or smaller. Before CTC detection can be applied in the early disease setting, sensitivity will need to be improved by at least 15-fold and combined with technology that minimizes false positives.